Do I need a prescription for Moclobemide 300mg tablets?

Moclobemide 300mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Moclobemide 300mg tablets?

Moclobemide 300mg tablets is the generic name. It is available under brand names including: Manerix 300mg tablets, Manerix 300mg tablets, Manerix 300mg tablets, Manerix 300mg tablets, Manerix 300mg tablets and 14 more. (Source: NHS dm+d — Actual Medicinal Products)

Moclobemide 300mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

300mg

Oral

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.

Active ingredients:

Moclobemide

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.03.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N06AG02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Moclobemide

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Moclobemide

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Moclobemide

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Moclobemide

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

19 branded products available

19 productsShow details

19 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Moclobemide on the MHRA register

Manerix 300mg tablets

Viatris UK Healthcare Ltd

Manerix 300mg tablets

CST Pharma Ltd

Moclobemide 300mg tablets

A A H Pharmaceuticals Ltd

Moclobemide 300mg tablets

Sandoz Ltd

Moclobemide 300mg tablets

Medihealth (Northern) Ltd

Manerix 300mg tablets

Waymade Healthcare Plc

Discontinued

Manerix 300mg tablets

Dowelhurst Ltd

Discontinued

Manerix 300mg tablets

Necessity Supplies Ltd

Discontinued

Manerix 300mg tablets

DE Pharmaceuticals

Discontinued

Moclobemide 300mg tablets

Teva UK Ltd

Discontinued

Moclobemide 300mg tablets

Kent Pharma (UK) Ltd

Discontinued

Moclobemide 300mg tablets

Alliance Healthcare (Distribution) Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£13.99indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

300 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Moclobemide 150mg/5ml oral suspension

Oral suspension

150mg/5ml

Same therapeutic group

Moclobemide 50mg/5ml oral suspension

Oral suspension

50mg/5ml

Same therapeutic group

Moclobemide 150mg tablets

Tablet

150mg

Same therapeutic group

Citalopram 30mg tablets

Tablet

30mg

Same BNF section

Escitalopram 15mg orodispersible tablets sugar free

Tablet

15mg

Same BNF section

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Moclobemide

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(3)

Depression in adults with a chronic physical health problem: recognition and management (CG91)

CG91

Clinical guideline

Updated Oct 2009

Social anxiety disorder: recognition, assessment and treatment (CG159)

CG159

Clinical guideline

Updated May 2013

Depression in adults: treatment and management (NG222)

NG222

NICE guideline

Updated Jun 2022

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Moclobemide

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42275011000001106

dm+d ID

42275011000001106

VTM (Virtual Therapeutic Moiety)

776812009

VMP (Virtual Medicinal Product)

42275011000001106

BNF code

04030200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N06AG02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

140 found

Half-life

1-2 hours

Mechanism

The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A.

Food interactions

3 warnings

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

95%

Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic…

Half-life

1-2 hours

1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted

Protein binding

50%

Approximately 50% (primarily to albumin) [L1350]

Volume of distribution

1-1.5 L/Kg

1-1.5 L/Kg [L1350]

Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.
Moclobemide…

Elimination

Moclobemide is almost completely renally excreted .
[L1350]

Clearance

30-78 L/h

Clearance of 30-78 L/h [L1350], mainly excreted in urine.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs). Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants [A31901].

Properties:

solid

Avg. mass: 268.74 Da

DrugBank indication

For the treatment of major depressive disorder and bipolar disorder .
[A31901]

Also known as(58)

4-Chlor-N-(2-morpholinoethyl)benzamid

Moclobemid

Moclobemida

Moclobemide

Moclobemidum

p-Chloro-N-(2-morpholinoethyl)benzamide

1.4.3.21

1.4.3.4

Dosage forms(12)

Solution (Oral) — 100.000 mg

Tablet (Oral)

Tablet, coated (Oral) — 150 mg

Tablet, film coated (Oral)

Tablet (Oral) — 100 mg / tab

Tablet, film coated (Oral) — 150 MG

Tablet, film coated (Oral) — 300 MG

Tablet (Oral) — 150 mg

Molecular properties(19)

Drug interactions(1548)

Known interactions with other medications. Always consult a healthcare professional.

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Moclobemide.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Moclobemide can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Moclobemide may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.

Check this interaction

Orphenadrine

Moderate

DB01173

Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Moclobemide.

Check this interaction

Pramipexole

Moderate

DB00413

Moclobemide may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Moclobemide may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Moclobemide may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Moclobemide.

Check this interaction

Sodium oxybate

Moderate

DB09072

Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Thalidomide

Moderate

DB01041

Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Dabrafenib

Unknown severity

DB08912

The serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib.

Check this interaction

Desmopressin

Unknown severity

DB00035

The risk or severity of hypertension can be increased when Desmopressin is combined with Moclobemide.

Check this interaction

Icosapent

Unknown severity

DB00159

The risk or severity of hypertension can be increased when Icosapent is combined with Moclobemide.

Check this interaction

Mesalazine

Unknown severity

DB00244

The risk or severity of hypertension can be increased when Mesalazine is combined with Moclobemide.

Check this interaction

Methylergometrine

Unknown severity

DB00353

The risk or severity of hypertension can be increased when Methylergometrine is combined with Moclobemide.

Check this interaction

Nabumetone

Unknown severity

DB00461

The risk or severity of hypertension can be increased when Nabumetone is combined with Moclobemide.

Check this interaction

Ketorolac

Unknown severity

DB00465

The risk or severity of hypertension can be increased when Ketorolac is combined with Moclobemide.

Check this interaction

Tolmetin

Unknown severity

DB00500

The risk or severity of hypertension can be increased when Tolmetin is combined with Moclobemide.

Check this interaction

Fenoprofen

Unknown severity

DB00573

The risk or severity of hypertension can be increased when Fenoprofen is combined with Moclobemide.

Check this interaction

Sulindac

Unknown severity

DB00605

The risk or severity of hypertension can be increased when Sulindac is combined with Moclobemide.

Check this interaction

Sulfasalazine

Unknown severity

DB00795

The risk or severity of hypertension can be increased when Sulfasalazine is combined with Moclobemide.

Check this interaction

Carprofen

Unknown severity

DB00821

The risk or severity of hypertension can be increased when Carprofen is combined with Moclobemide.

Check this interaction

Phenmetrazine

Unknown severity

DB00830

The risk or severity of hypertension can be increased when Phenmetrazine is combined with Moclobemide.

Check this interaction

Diflunisal

Unknown severity

DB00861

The risk or severity of hypertension can be increased when Diflunisal is combined with Moclobemide.

Check this interaction

Meclofenamic acid

Unknown severity

DB00939

The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Moclobemide.

Check this interaction

Oxaprozin

Unknown severity

DB00991

The risk or severity of hypertension can be increased when Oxaprozin is combined with Moclobemide.

Check this interaction

Balsalazide

Unknown severity

DB01014

The risk or severity of hypertension can be increased when Balsalazide is combined with Moclobemide.

Check this interaction

Dutasteride

Unknown severity

DB01126

The risk or severity of hypertension can be increased when Dutasteride is combined with Moclobemide.

Check this interaction

Finasteride

Unknown severity

DB01216

The risk or severity of hypertension can be increased when Moclobemide is combined with Finasteride.

Check this interaction

Ephedrine

Unknown severity

DB01364

The risk or severity of hypertension can be increased when Moclobemide is combined with Ephedrine.

Check this interaction

Magnesium salicylate

Unknown severity

DB01397

The risk or severity of hypertension can be increased when Moclobemide is combined with Magnesium salicylate.

Check this interaction

Salsalate

Unknown severity

DB01399

The risk or severity of hypertension can be increased when Moclobemide is combined with Salsalate.

Check this interaction

Choline magnesium trisalicylate

Unknown severity

DB01401

The risk or severity of hypertension can be increased when Moclobemide is combined with Choline magnesium trisalicylate.

Check this interaction

Antrafenine

Unknown severity

DB01419

The risk or severity of hypertension can be increased when Moclobemide is combined with Antrafenine.

Check this interaction

Tiaprofenic acid

Unknown severity

DB01600

The risk or severity of hypertension can be increased when Moclobemide is combined with Tiaprofenic acid.

Check this interaction

Epicaptopril

Unknown severity

DB02032

The risk or severity of hypertension can be increased when Moclobemide is combined with Epicaptopril.

Check this interaction

Taxifolin

Unknown severity

DB02224

The risk or severity of hypertension can be increased when Moclobemide is combined with Taxifolin.

Check this interaction

Oxyphenbutazone

Unknown severity

DB03585

The risk or severity of hypertension can be increased when Moclobemide is combined with Oxyphenbutazone.

Check this interaction

1-benzylimidazole

Unknown severity

DB04581

The risk or severity of hypertension can be increased when Moclobemide is combined with 1-benzylimidazole.

Check this interaction

Showing 50 of 1548 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid excessive or chronic alcohol consumption.

Advice

Avoid tyramine-containing foods and supplements. Avoid excess consumption (<100mg) of tyramine. Food that contains tyramine includes yogurt, aged cheese, ripe bananas, wine, and sourdough bread.

Advice

Take after a meal.

Toxicity & overdose

LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures .
[A31903]
The effects of moclobemide alone in overdose are negligible, even with high volume ingestion. However, moclobemide overdose with a serotonergic agent (even in small, therapeutic doses) can cause severe serotonin toxicity. The elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses .
[A31903]

How it works

Mechanism of action

The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms [A31901][A31902].

Pharmacodynamics

A selective, reversible inhibitor of monoamine oxidase (MAO) which increases the [A31901]. Besides its presence in sympathetic nerves, there is an abundant evidence that MAO-A is localized in noradrenergic neurons in the locus coeruleus and MAO-B is closely associated with serotonergic neurons of the raphe nucleus [A31901].

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first-pass metabolism reduces bioavailability to about 56% following administration of one dose, but increases to 90% with steady-state dosing as a result of saturation of the first pass effect.

Peak plasma concentrations are reached within 0.3 - 1 hours following oral administration with a terminal half-life of 1.6h .
[L1350]

Half-life

1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted

Protein binding

Approximately 50% (primarily to albumin) [L1350]

Volume of distribution

1-1.5 L/Kg [L1350]

Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.
Moclobemide is a substrate of CYP2C19. Although it acts as an inhibitor of CYP1A2, CYP2C19, and CYP2D6 .
[A31901]

Route of elimination

Moclobemide is almost completely renally excreted .
[L1350]

Clearance

Clearance of 30-78 L/h [L1350], mainly excreted in urine.

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Amine oxidase [flavin-containing] A

BE0002198

MAOA

antagonist

inhibitor

Specific functionflavin adenine dinucleotide binding

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:18391214 PMID:20493079 PMID:24169519 PMID:8316221

Preferentially oxidizes serotonin .
PMID:20493079 PMID:24169519
Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity)

Amine oxidase [flavin-containing] B

BE0004909

MAOB

antagonist

Specific functionelectron transfer activity

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Preferentially degrades benzylamine and phenylethylamine PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Amine oxidase [flavin-containing] B

BE0002196

MAOB

antagonist

Specific functionelectron transfer activity

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Metabolizing enzymes(5)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2C9Cytochrome P450 2C9

substrate

CYP2C19Cytochrome P450 2C19

substrate

inhibitor

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

MAOAAmine oxidase [flavin-containing] A

inhibitor

MAOBAmine oxidase [flavin-containing] B

inhibitor

Scientific references(3)

Bonnet U.

Moclobemide: therapeutic use and clinical studies.

CNS Drug Review

2003 Spring9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x

PMID: 12595913 DOI: 10.1111/j.1527-3458.2003.tb00245.x

Gram L.F., Guentert T.W., Grange S., Vistisen K., Brosen K.

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.

Clinical Pharmacology Therapeutics

1995 Jun57(6):670-7. doi: 10.1016/0009-9236(95)90230-9

PMID: 7781267 DOI: 10.1016/0009-9236(95)90230-9

Isbister G.K., Hackett L.P., Dawson A.H., Whyte I.M., Smith A.J.

Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.

British Journal of Clinical Pharmacology

200356(4):441-450. doi: 10.1046/j.1365-2125.2003.01895.x

PMID: 12968990 DOI: 10.1046/j.1365-2125.2003.01895.x

ATC classification(1 code)

ATC N06AG02

Affected organisms(1)

Humans and other mammals

International brands(1)

Experimental properties(5)

Commercial products(21)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Moclobemide

DB01171

CAS number

71320-77-9

UNII (FDA)

PJ0Y7AZB63

InChI Key (molecular fingerprint)

YHXISWVBGDMDLQ-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

7943

ChEBI

83531

PubChem Compound

4235

PubChem Substance

46504667

KEGG Drug

D02561

ChemSpider

4087

BindingDB

15613

PharmGKB

PA452615

Therapeutic Targets Database

DAP000576

Wikipedia

Moclobemide

ChEMBL

CHEMBL86304

ZINC

ZINC000019606670

RxCUI

30121

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

International reference pricing

11 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.26/tablet

To $1.34/tablet

Apo-Moclobemide 100 mg Tablet

$0.26/tablet

Novo-Moclobemide 100 mg Tablet

$0.26/tablet

Nu-Moclobemide 100 mg Tablet

$0.26/tablet

Apo-Moclobemide 150 mg Tablet

$0.38/tablet

Novo-Moclobemide 150 mg Tablet

$0.38/tablet

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Moclobemide 300mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(3)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
8

Chemical identifiers

Moclobemide

Additional database identifiers

International reference pricing

DrugBank citations

Moclobemide 300mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(3)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science8

Chemical identifiers

Moclobemide

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
8